Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2008

AMRI Adds Non-GMP Manufacturing Services with Expansion of India Facility

  • AMRI reports that is has expanded the multipurpose pilot plants in Aurangabad, India, providing non-GMP manufacturing services up to a 1,000-liters scale.

    The move increases AMRI’s ability to provide customized pilot-scale materials for customers. In addition to being a stand-alone provider, the new facility will serve as an extension to AMRI's kilo-lab capabilities in Hyderabad, India, which operates to 100 liters in scale.

    Certain plant production will be dedicated to making starting materials for AMRI's U.S. manufacturing facilities, significantly diminishing that plant’s reliance on external resource providers, the firm notes.

    “We look forward to realizing cost savings at our U.S. manufacturing operations by becoming our own provider for some raw materials, eliminating third-party costs in both money and lead time,” says chairman, CEO, and president, Thomas E. D’Ambra, Ph.D.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »